A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]

Table 3 Summary of safety data

	Placebo	Etoricoxib 90 mg	Naproxen 1000 mg
	(N = 357)	(N = 353)	(N = 181)
	n (%)	n (%)	n (%)
Number of patients:
With any drug-related clinical adverse event	55 (15.4)	82 (23.2) ^†	35 (19.3)
With any serious clinical adverse event^‡	3 (0.8)	7 (2.0)	3 (1.7)
Discontinued due to clinical adverse event	6 (1.7)	9 (2.5)	5 (2.8)

^† p < 0.05 vs placebo.
^‡ Serious adverse events were: placebo (3 patients) – thrombophlebitis, atrial fibrillation, and pneumothorax; etoricoxib (7 patients) – pulmonary embolism, angina pectoris, thyroid cancer, duodenal ulcer, hip pain, femoral fracture, and traumatic arthropathy plus corneal degeneration (in the same patient); naproxen (3 patients) – hypertension, intervertebral disc displacement, and retinal detachment.

ISSN: 2731-4553